fashion -WSS

fashion

author：hotspot 2025-09-27 15:19:39 - browse：5935

Adobe

The Food and Drug Administration has cleared Otsuka Pharmaceutical’s digital treatment for major depressive disorder, offering a new option for millions of people who struggle with the stubborn mental health condition.

Called Rejoyn, the smartphone-based treatment for major depressive disorder symptoms was developed with digital health company Click Therapeutics, and it is intended for use by prescription alongside antidepressants. The six-week program delivers a novel “cognitive-emotional training” technique, in which people are asked to identify and recall faces showing different emotions. Researchers hypothesize that the technique targets the brain’s dorsolateral prefrontal cortex and the amygdala and may “enhance cognitive control over emotional information processing.” Patients also receive cognitive behavioral therapy.

Rejoyn has been in development since 2018, and Otsuka is the first drug company to receive FDA clearance for a digital treatment for a mental health condition. But that landmark comes amid many questions about whether such digital therapeutics deliver their advertised results — and whether they can gain traction with clinicians, insurers, and patients. Prescription digital therapeutics have yet to see a blockbuster success, and several companies have gone out of business trying to create one.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Judge sides with young activists in first

WSS

Man pleads guilty to raping Ohio girl who ended up traveling across state lines for abortion

Accuser says Kevin Spacey grope wasn't a caress: ‘It was like a cobra ... angry’

Biden's Plan B on student loan forgiveness relies on Higher Education Act: What to know

A bus careens into a gulch in southern Mexico, leaving 27 people dead

Health AI: on the border between health care and tech

BMS, looking to build heart drug business, turns to AI for diagnosis

entertainment

fashion

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

Psychedelics group wrestles with new pharma identity

Dramatic video released of Russian fighter jets 'harassing' US drones over Syria

Bright Health sells Medicare Advantage business to Molina

1 in 4 Americans hadn't contracted COVID by the end of 2022, CDC estimates

Medicare details structure of new drug price negotiation program

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Bright Health sells Medicare Advantage business to Molina

Princess Kate attends Wimbledon with Roger Federer: See the photos

Wikipedia

The leaders of Italy and Poland say European Union should focus on stopping migration

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

Adele warns fans about throwing things at performers onstage

Surge in Apellis stock fueled by confidence in safety of its eye drug

Judge sides with young activists in first

Biogen’s boardroom scandal saddles CEO with first crisis

entertainment

focus

entertainment

entertainment